Track market-moving stories before they get noisy

BERKELEY, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Deep Isolation Nuclear, Inc. (“Deep Isolation” or the “Company”), a leading innovator in nuclear waste disposal technology, today announced that Technology Demonstration Lead Jon Tedrick has relocated to Texas to support execution of the Company's demonstration program at the Deep Borehole Demonstration Center (DBDC) near Cameron, Texas. The relocation reflects Deep Isolation's commitment to establishing a strong field presence as the project progresses toward active operations.

The demonstration program is designed to validate key components of the Company's deep borehole disposal solution under representative field conditions. Earlier this year, Deep Isolation and its collaborators marked the launch of the project with a groundbreaking ceremony at the DBDC. Through the project, Deep Isolation plans to demonstrate the construction of a deep borehole repository using standard oil and gas drilling practices, full-scale canister emplacement and retrieval operations using its Universal Canister System (UCS), and simulated surface handling operations.

Tedrick's relocation coincides with Deep Isolation’s recent selection for the U.S. Department of Energy's ARPA-E SCALEUP Ready program, which is designed to accelerate promising energy technologies toward commercial deployment. The program provides up to $20 million to the Company to support testing and demonstration activities. The Deep Isolation project brings together a world-class team, including Westinghouse, NAC International (TYO: 7004), Halliburton (NYSE: HAL), Occlusion Nuclear Solutions, Amentum (NYSE: AMTM) and the Deep Borehole Demonstration Center, to demonstrate an integrated solution for the storage, transportation and permanent disposal of advanced reactor and nuclear recycling waste.

As Technology Demonstration Lead, Tedrick is responsible for coordinating field execution activities, supporting engagement with project collaborators and contractors, and helping oversee preparations for upcoming demonstration activities at the Cameron site. Tedrick brings more than 28 years of drilling and project management experience spanning mining, geothermal, environmental and energy applications, including leadership of major drilling programs for the U.S. Department of Energy.

"The Cameron demonstration program is an important milestone in our path to commercialization and a critical opportunity to validate our technology at full scale,” said Rod Baltzer, CEO of Deep Isolation. "As we move closer to field execution, having Jon on the ground strengthens on-site coordination and helps ensure we are prepared to successfully deliver this first-of-its-kind demonstration. His extensive drilling and project leadership experience will be invaluable as we advance toward active operations."

"Throughout my career, I have worked on complex drilling projects across the energy, mining and environmental sectors, but few have combined this level of technical innovation with such an important mission," said Tedrick. "Relocating to Texas allows me to work closely with our field team as we prepare for the next phase of execution. I am excited to help demonstrate how proven drilling technologies can be applied to address one of the nuclear industry's most significant challenges."

As interest in advanced nuclear energy continues to grow, the need for practical, scalable solutions for the management and disposal of spent nuclear fuel and high-level radioactive waste has become increasingly important. Supported by ARPA-E's SCALEUP Ready program and a consortium of leading industry collaborators, the Cameron project is designed to advance the technical, operational and regulatory foundations needed for future deployment of an integrated solution for the storage, transportation and permanent disposal of advanced reactor and nuclear recycling waste.

About Deep Isolation

Deep Isolation is the first company to undertake development of technologies for nuclear waste disposal in deep boreholes. When commercialized, Deep Isolation’s solution will offer a unique solution to help countries identify, plan for and complete the necessary steps to dispose of their nuclear waste inventories. With over 100 patents issued to date, Deep Isolation’s technology is being designed to leverage proven drilling practices to allow safe isolation of waste deep underground in horizontal, vertical, or slanted borehole repositories. Deep Isolation’s Universal Canister System was developed through a three-year project funded by the U.S. Department of Energy’s Advanced Research Projects Agency–Energy and is engineered to support integrated management of spent fuel and high-level radioactive waste from legacy and advanced reactors across storage, transportation, and eventual disposal. In January 2026, Deep Isolation launched a full-scale, at-depth deep borehole Commercialization Pilot for its solution at Cameron, Texas, in collaboration with the Deep Borehole Demonstration Center, Halliburton (NYSE: HAL), Amentum (NYSE: AMTM), NAC International, and Occlusion Nuclear Solutions.

For more information, visit: https://www.deepisolation.com

Media Contact:
Sophie McCallum
[email protected]

Investor Contact:
Caldwell Bailey
[email protected]

Forward-Looking Statements

Statements contained in this news release that are not historical facts are “forward-looking information” or “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding our plans, objectives and expectations for our business, the future growth of our business and the nuclear energy and nuclear waste disposal industries as a whole, and future benefits expected to arise from our strategic partnerships. In certain cases, forward-looking statements can be identified by the use of words and phrases or variations of words and phrases or statements such as “may,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “will,” “could,” “project,” “target,” “potential,” “continue” and similar expressions. Forward-looking statements are based on management’s belief and assumptions, including current expectations and projections about future events and trends, and on information currently available to management.

Forward-looking statements in this or any other news release are subject to a number of risks, uncertainties, and assumptions that could cause actual results to be materially different from those expressed or implied by such forward-looking statements. Such risks, uncertainties, and assumptions are subject to a number of factors, including, among others: the failure of a market to develop for our deep borehole disposal solutions as quickly as we expect or at all; a failure of demand for our solution to develop sufficiently; regulatory and legal developments, including issues relating to obtaining regulatory approvals or permissions on the timelines we expect or at all; our lack of profitability; delays or failure in our initiative to complete a full-scale, at-depth demonstration of our Universal Canister System and our deep borehole solution; our failure to enter into contracts with customers or, once we do enter into contracts, to continue such contractual relationships or to receive new contract awards; our dependency on governmental contracts and awards and our ability to finalize negotiations on same; our failure to manage our growth effectively or to execute our business plan; our failure to sustain and expand relationships with governmental entities and strategic partners; a failure in the assumptions or analyses we have used in supporting forecasts or plans; our inability to commercialize our products at scale; the development or deployment of other technologies or solutions supplanting or competing with our technologies; challenges to our intellectual property; failures to protect, maintain, enforce, and enhance our intellectual property, and claims by others of intellectual property infringement; political and public perceptions of nuclear energy, including perceptions as to accidents or other high-profile events involving nuclear power facilities or radioactive materials; our liquidity and ability to raise capital; any inability to control operating and project costs and project delays or other project-related problems; security (including cybersecurity) breaches or disruptions; geopolitical, macroeconomic, domestic events or crises, including supply chain disruptions and other risks and uncertainties outside of our control; weather and effects of climate change; and litigation or legal proceedings that may be brought against us.

The foregoing is not an exhaustive list of all the factors that may cause any forward-looking statements to prove inaccurate or our actual results to differ materially from our expectations and forecasts. Moreover, we operate in a highly regulated environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements, and we cannot guarantee future results, performance, or achievements. Accordingly, readers should not place undue reliance on forward-looking statements. We undertake no obligation to update any forward-looking statements for any reason after the date of this release or to conform these statements to actual results or revised expectations, except as required by law.

Additional information concerning the factors above and other factors will be found in the Company’s public filings with the Securities and Exchange Commission (the “SEC”), including the sections titled “Forward-Looking Statements” and “Risk Factors” in the Company’s Reports on Form 10-K and 10-Q for the fiscal year ended December 31, 2025 and the quarter ending March 31, 2026, respectively, as filed with the SEC on March 30, 2026, our Form S-1, originally filed August 18, 2025 and subsequently amended, our Proxy Statement for our 2026 Annual Meeting as filed on April 29, 2026, and in filings with the SEC that will be made in the future. The Company’s SEC filings are available free of charge at www.sec.gov or upon written request to Deep Isolation at [email protected] or [email protected].

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/344d17f4-c753-4e58-8a38-1605dc59ab79

FUTU's 24% plunge, regulatory penalty and strong user growth leave investors weighing whether its healthy platform is still worth the risk.

NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Futu Holdings Limited (NASDAQ: FUTU) resulting from allegations that Futu may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Futu securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/cases/futu-holdings-limited/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On May 22, 2026, Reuters published an article entitled "China to crack down on 'illegal' cross-border securities" The article stated that China "announced a major crackdown on cross-border investment on Friday and said it would punish ​brokers it accused of illegally moving money to foreign markets, sending their shares plunging." Further, "online brokers Tiger, Futu and Longbridge would be penalised for soliciting ‌business in China without an onshore licence, the securities regulator said."

On this news, Futu American Depositary Shares ("ADSs") fell 27.5% on May 22, 2026.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Shares of Seagate Technology (STX +1.23%) have become one of the more surprising artificial intelligence (AI) winners in the market. Hard drives are not as glamorous as graphics processing units (GPUs) or cloud software. But data centers still need a place to store the flood of data created by AI applications, and investors have started treating Seagate as a front-line beneficiary of that build-out.

The move has been extraordinary. The storage stock is more than 700% over the past year as of this writing, and it jumped about 9% on Monday alone and is up sharply on Tuesday morning, too. Even after a run like that, could shares keep rising? If AI-driven demand keeps outstripping supply and Seagate continues to expand margins, the stock could still have room to run.

Here's a closer look at the business behind the move.

Image source: Getty Images.

AI is turning hard drives into a growth story Seagate's fiscal third quarter of 2026 (the period ended April 3, 2026) showed just how incredible the business's momentum is. Revenue rose 44% year over year to $3.11 billion, while non-GAAP (adjusted) gross margin expanded to 47% from 36.2% in the year-ago quarter. Adjusted earnings per share more than doubled to $4.10.

Additionally, Seagate's adjusted gross margin has climbed from 40.1% in fiscal Q1 to 42.2% in fiscal Q2. It reached 47% in fiscal Q3. And management guided for fiscal fourth-quarter revenue of about $3.45 billion at the midpoint, implying another sharp increase.

The driver is Seagate's nearline business, which supplies high-capacity drives used in data centers. They store enormous amounts of data at a low cost per terabyte.

"Today, AI sits at the center of nearly all customer demand conversations," said Seagate CEO Dave Mosley in the company's fiscal third-quarter earnings call.

Management said nearline products accounted for close to 90% of total exabyte shipments in the March quarter. Even more, Seagate said nearline capacity is almost fully allocated through calendar 2027, supported by supply agreements with nearly all major cloud and hyperscale customers.

That visibility is important -- and it's central to the bull case for the stock.

After all, storage has historically been cyclical and unpredictable, with supply and demand swinging sharply. But today's demand backdrop looks unusual, not just because of visibility, but also because Seagate has another main lever beyond unit growth: it is trying to push more capacity into each drive.

This is where heat-assisted magnetic recording (HAMR) comes in. Seagate's Mozaic 4+ platform can deliver up to 44 terabytes per drive, more than 30% higher capacity than its first-generation Mozaic drives, while using the same number of disks and heads. Seagate also said it began revenue shipments of Mozaic 4 in late March and expects that platform to represent a majority of HAMR exabyte shipments exiting calendar 2026.

"We are going faster than what we were thinking on the transition to HAMR," said Seagate chief financial officer Gianluca Romano during the call.

Today's Change

(

1.23

%) $

12.54

Current Price

$

1031.34

Can the stock keep rising? The bull case is fairly simple. Seagate has tight supply, strong demand, a higher-capacity roadmap, and pricing visibility that extends well beyond the next quarter. In addition, management said it now expects annual revenue growth of at least 20% over the next few years, up from its prior low-to-mid-teens target.

Additionally, the model is throwing off significant cash. Seagate generated $953 million of free cash flow in fiscal Q3 -- its highest level in more than a decade, and reduced gross debt by about $1.1 billion through the first nine months of fiscal 2026.

Still, investors should be careful.

The stock's market capitalization is more than $230 billion as of this writing, and the stock trades at nearly 100 times earnings. A valuation like this assumes the current boom lasts and that margins stay high as HAMR ramps.

And the company's own filings still point to the old risks. Seagate says nearline storage sales can vary because of the timing of cloud service provider spending, product qualification cycles, and customers' ability to source other parts needed to build data centers. In addition, if supply eventually catches demand, pricing power can fade quickly in hardware markets like Seagate's.

So, is Seagate stock a buy?

I think the stock could keep moving higher if AI storage demand remains stronger than supply through 2027. The business momentum is undeniable, and Seagate's HAMR roadmap gives it a tangible way to turn demand into higher capacity and better margins.

But just because there's a chance it could keep moving higher doesn't make the stock a buy.

After a more than 700% one-year move, I'd approach shares cautiously here. For investors who think we're still early in the AI boom, a small position may make sense. But at this valuation, the stock needs the boom to continue with very few interruptions. After all, this is still a cyclical hardware company -- even if the current cycle looks far stronger than usual.

New program empowers technology partners to build native apps, driving a collaborative identity security "app economy" for customers June 16, 2026 08:00 ET  | Source: SailPoint Technologies, Inc.

AUSTIN, Texas, June 16, 2026 (GLOBE NEWSWIRE) -- SailPoint, Inc. (Nasdaq: SAIL), a leader in enterprise identity security, today announced an important enhancement to its Technology Alliance Partners Program with new Unified Platform Access. As organizations increasingly cite integration and implementation as the single biggest barrier to security maturity, the new initiative provides technology partners with frictionless, direct access to the SailPoint platform. SailPoint partners can now move beyond basic integrations to build native, highly automated, and commercially viable applications that extend the power of identity security.

The Unified Platform Access solution empowers a broad ecosystem of technology partners and systems integrators to innovate and build on SailPoint's Atlas foundation. Through a collaborative commercial framework that combines a tiered annual membership fee with a shared-success revenue model, partners gain access to advanced integration tools, rigorous certifications, and joint go-to-market support. This aligned approach ensures mutual growth while fostering the development of high-value, third-party solutions that help our joint customers solve complex, industry-specific security challenges.

Chris Gossett, Chief Growth Officer at SailPoint commented:
"Our mission is to provide enterprises with a comprehensive, intelligent, and adaptive identity security solution, and a critical part of that strategy is fostering a vibrant and innovative partner ecosystem. The Unified Platform Access program marks the evolution of our technology partner strategy. We are moving well beyond basic integrations to truly empower our partners to build their own unique and valuable solutions directly on the SailPoint Platform. This creates a powerful 'app economy' of innovation that will directly benefit our customers by giving them more ways to unify and enhance their security posture."

With Unified Platform Access, technology partners can easily deliver certified integrations, granting joint customers access to a wider array of trusted and certified solutions. Rather than spending months custom-coding bespoke integrations for specialized HR, IT, or industry-specific systems, partners can now seamlessly unify their SailPoint deployment with other critical technologies, instilling confidence that the integrations are validated by SailPoint. This approach ensures that joint customers can maximize the value of their identity security investment and address specific needs with a proven, trusted ecosystem of technology partners.

Launching with strong industry momentum, an inaugural group of partners is already building on SailPoint’s Unified Platform Access including: Aquera, Cerby, Grip Security, Key2XS, Living Security, Opnova, Orchid Security, RedBlock Security, and Splan.

Lior Yaari, CEO and Founder, Grip Security said:
"The ability to build directly on the SailPoint platform is a game-changer. The Unified Platform Access gives us the tools and access we need to develop more sophisticated and deeply integrated solutions for our mutual customers. We are excited to be a part of this program and to work more closely with SailPoint to advance the future of identity security.”

Mike Siegel, President, Living Security said:
"The Unified Platform Access program is a strong acknowledgement from SailPoint that the ecosystem plays a valuable role in driving customer success and value. We’re delighted to evolve our membership and help grow our partnership with SailPoint.”

Partners interested in the Unified Platform Access can learn more here.

About SailPoint
SailPoint (Nasdaq: SAIL) is defining the new era of adaptive identity security. In a world where non-human identities now significantly outnumber humans, our AI-powered platform unifies identity, security, and data intelligence to protect today’s enterprise from advanced identity-based threats. We deliver the identity solution that spans both the breadth of identities and the depth of context needed to drive real-time access with confidence. Built on principles like zero-standing privilege and contextualized risk, our SailPoint platform transforms identity from a point of vulnerability into a powerful security advantage. Trusted by many of the world's leading organizations, SailPoint secures the enterprise with intelligent, autonomous identity security.

Media relations for SailPoint
Shannon Paulk
Sr. Manager, Corporate Communications
303-748-2275
[email protected]

SailPoint management touted robust Q1 growth on June 9, 2026 -- but the forward outlook told a different story, and the stock fell approximately 12% in a single session.

, /PRNewswire/ -- Investors in SailPoint, Inc. (NASDAQ: SAIL) lost approximately 12% of their holdings on June 9, 2026, after the Company's Q1 FY2027 earnings call revealed a weaker forward outlook that contradicted the optimistic tone of its results. Shareholders who suffered a loss are encouraged to submit their information here . You may also contact Joseph E. Levi, Esq. via email at [email protected]  or by telephone at (212) 363-7500.

SailPoint's Q1 FY2027 press release highlighted an EPS of $0.05 versus a consensus estimate of $0.04 and year-over-year revenue growth of approximately 22%. During the accompanying earnings call, management provided guidance that included a projected loss for the coming quarter and commentary regarding foreign-exchange headwinds affecting ARR growth. The Company's own forward guidance diverged sharply from the growth trajectory presented in its headline figures.

Prior to the June 9 release, SailPoint's stock had appreciated significantly over the preceding weeks. Market expectations appeared elevated heading into the announcement, with analysts generally anticipating strong quarterly results. Following the earnings release and accompanying guidance, the stock declined sharply, reflecting investor concern about the company's outlook.

If you purchased SailPoint shares and suffered a loss, click here to discuss your legal rights . You may also contact Joseph E. Levi, Esq. via email at [email protected]  or by telephone at (212) 363-7500.

WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.

Frequently Asked Questions About the SAIL Investigation

Q: Who is conducting the SAIL investigation?  A: Levi & Korsinsky, LLP is investigating potential securities law concerns on behalf of investors who purchased SAIL securities and suffered losses. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.

Q: Which statements are being investigated as potentially misleading?  A: The investigation concerns whether SailPoint adequately disclosed its outlook and expected future performance, including guidance provided in connection with its June 9, 2026 earnings release. Following the release and management's discussion of future expectations, the stock declined approximately 12%.

Q: What do SAIL investors need to do right now?  A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected]  or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.

Q: What if I already sold my SAIL shares -- can I still recover losses?  A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought SAIL and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate?  A: Nothing. Securities investigations are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: Do I need to go to court or give testimony?  A: No. Participating in the investigation does not require court appearances or depositions.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

SOURCE Levi & Korsinsky, LLP

SailPoint, Inc. (SAIL) Analyst/Investor Day Transcript

Astera Labs stock is showing notable weakness. Why is ALAB stock falling? Stock Pulls Back After Monday RallyAstera Labs is giving back part of Monday's advance. Chip and semiconductor names rallied broadly at the start of the week as progress toward a U.S.-Iran memorandum of understanding boosted demand for growth stocks that tend to benefit from cheaper energy, softer inflation pressure and a lower probability of additional rate hikes.

The move in oil spilled into the rates market. The 10-year Treasury yield eased 3 basis points to around 4.46%, the 2-year yield fell 4 basis points to 4.05%, and the 30-year held near 4.97%. President Trump said on Truth Social that ships were already moving oil out of the strait. Senior officials added that traffic would increase immediately even though full reopening will take longer because of mine‑clearing operations.

Stock Has Seen a Massive RunTuesday's pullback comes after an exceptional run for Astera Labs. The stock has traded between $84.78 and $398.13 over the past twelve months, which represents roughly a four-times move during that period. When a stock posts gains of that size, short-term volatility or profit‑taking after a strong single‑day rally is common.

Astera Labs Stock: Key Levels To WatchAstera Labs continues to hold a strong upward structure. The stock trades 12.7% above the 20-day simple moving average at $327.27 and more than 50% above the 50-day simple moving average at $242.21. Moves this extended often signal powerful momentum, but they can also create conditions where pullbacks develop quickly. The broader trend remains constructive because the 50-day average sits above the 200-day average, a golden cross that formed in May.

Momentum is the main near-term focus. RSI is at 70.35, which places the stock in overbought territory. This suggests the recent advance has been aggressive and that the stock may react more sharply to any cooling in risk appetite. RSI helps identify when a move has accelerated too quickly. Readings above 70 often align with consolidation phases or short‑term pullbacks.

Key Resistance: $372.50 This level sits just above the current trading area and has acted as a ceiling where rebounds have struggled to push through. Key Support: $303.00 This is a nearby zone where buyers previously stepped in and a logical area traders may watch if the current pullback deepens. ALAB Shares Are FallingALAB Price Action: Astera Labs shares were down 5.13% at $369.22 at the time of publication on Tuesday. The stock is approaching its 52-week high of $398.13, according to Benzinga Pro.

Image: Piotr Swat/Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

In June, a Chinese lab released a frontier-grade language model, GLM-5.2 from Zhipu AI (still private), under a permissive open-source license with a one-million-token context window. A week earlier, Moonshot AI (private) shipped a trillion-parameter open model built for coding. Alibaba Group (BABA) saw its Qwen family cross one billion downloads on Hugging Face in January, passing Meta Platforms (META) and its Llama line as the most-downloaded open models on earth. Open weights have cracked the frontier open. As the model itself becomes a commodity, the question for investors now is — where does the value go next? Much of the answer sits inside the ROBO Global Artificial Intelligence Index (THNQ).

Key Takeaways (as of June 2026): Open-weight models now rival the closed frontier on coding tasks at a fraction of the cost. Alibaba’s Qwen alone passed one billion downloads in January 2026. As models commoditize, the value moves to serving them. Nebius Group (NBIS) reports a customer cutting inference costs up to 26x. Meanwhile, Cloudflare (NET) now serves over 70 models at the edge. Microsoft (MSFT) CEO Satya Nadella now frames the divide as “human capital and token capital.” THNQ’s 53 holdings span both the open-model makers and the infrastructure beneath them. See more: AI Agent Infrastructure: Why Enterprises Need a Control Plane

The price of intelligence is falling fast. The bigger question is where those savings get redeployed. The inference, edge, and silicon sections below name the companies collecting them.

Are Open-Source AI Models Closing the Gap With GPT & Claude? The gap between open and closed AI has narrowed to single digits on the benchmarks that advisors should care about — the ones that track real work. Open-weight systems from DeepSeek, Moonshot, and Zhipu (all private) now post coding scores within a few points of the best closed models. They also do it at a tenth to a thirtieth of the cost per token. Alibaba’s Qwen crossed one billion Hugging Face downloads in January 2026 and represents more than 50% of all open-model downloads globally. Meta’s Llama 4, released in 2025, remains open-weight and natively multimodal.

For most enterprise tasks, document analysis, customer triage, code review, and structured extraction, the open model is now the rational default on cost and data-privacy grounds alone. The frontier labs keep a real edge at the bleeding edge of novel capability, but that edge narrows with each quarterly release. The model, once the moat, is becoming the commodity input.

How Distillation & Agent Swarms Make Open AI Models Production-Ready Two mechanisms are collapsing the capability gradient. The first is distillation. This is when a large “teacher” model generates high-quality reasoning traces, and a small “student” model trains on them, inheriting the capability without the compute. These can oftentimes be run on third-party clouds, or even self-owned hardware (including some consumer grade). The second is self-improving harnesses: a model proposes its own tasks, solves them, grades itself, and reinforces the better answers, compounding capability inside a company’s own walls with no data leaving the building.

Then those models get deployed in parallel. Agent fan-outs and swarms break a complex job into pieces and dispatch many specialized sub-agents at once, then merge the results. This is the expansion that matters: AI is moving past efficient problem-solving in the digital world toward learning how to solve, and actually being deployed, across multi-step, linked, and unpredictable real-world task sets. It is the same arc that we covered in Physical AI Goes Live, now playing out in software and on the factory floor at once.

Satya Nadella on Human Capital & Token Capital On June 14, Satya Nadella published an essay arguing that a frontier without an ecosystem is not stable, and it reframed the whole debate. His line: “Every company is going to have to build what I think of as human capital and token capital.” Human capital is the judgment and pattern recognition of its people. Token capital is the AI capability that a firm builds and owns. His warning to staff was blunter: avoid “tokenmaxxing,” or routing every task through an expensive frontier model when a cheaper specialized one would do. Frontier AI for frontier work, and open, distilled models for the rest.

We made the same call from a different door. After the HumanX conference in March, we wrote that there are now two types of companies: the first treats headcount and agentic token workflows as equally important inputs into how the business runs, and the second is still in discovery, without a real AI strategy. The gap between them widens by the quarter. Nadella’s framing and ours converge on one point: the durable asset is the learning loop a company owns and keeps improving, while a rented model is only an input.

Where AI Value Accrues: Inference, Edge & Custom Silicon Follow the compute. Inference, the work of running a model rather than training it, now consumes roughly two-thirds of all AI compute, up from one-third in 2023. When the model weight is free, the cost that remains is the serving of it, and that is where the margin lives.

Nebius Group (NBIS) built its Token Factory for exactly this moment: a managed platform serving more than 40 open models. One customer, the technology investor Prosus (PRX.AS), reported up to 26x cost reduction versus proprietary models. Another runs up to 200 billion tokens per day. Cloudflare (NET) routes inference across more than 70 models from data centers in hundreds of cities, placing the model next to the user, and acquired Replicate in April 2026 to deepen that catalog. 

Underneath both, custom silicon is taking share: ASIC-based AI servers are forecast to reach 27.8% of AI server shipments in 2026, per TrendForce. MediaTek (2454.TW) projects more than $1 billion in AI ASIC revenue this year, Astera Labs (ALAB) grew first-quarter revenue 93% to $308 million on AI connectivity, and Credo Technology (CRDO) guided to roughly 120% revenue growth for its fiscal 2026. The weight trends toward zero. The network, the serving stack, and the silicon do not.

Frequently Asked Questions Are open-source AI models actually competitive with closed models like GPT and Claude? On practical benchmarks, increasingly yes. Zhipu AI open-sourced GLM-5.2 on June 13, 2026 under an MIT license with a one-million-token context window. Early comparisons place it level with or ahead of leading closed models on math reasoning, though Zhipu published no official benchmarks at launch. Alibaba’s Qwen and DeepSeek’s latest models now score within single digits of the closed frontier on coding, at roughly a tenth to a thirtieth of the cost per token. Qwen alone passed one billion downloads in January 2026.

If AI models are becoming “free” or “too cheap to measure” when combined with increasingly smarter, more token-efficient setups and harnesses, where does the investment value go? To inference, delivery, and expansion of automation in the real world — including connectivity and robotics applications. Running  models now consume about two-thirds of AI compute. Nebius (NBIS) reports up to 26x cost reductions on its open-model serving platform and Cloudflare (NET) serves more than 70 models from its edge network. Both are capturing recurring economics that the model layer is losing.

What is “token capital”? A term from Microsoft (MSFT) CEO Satya Nadella’s June 2026 essay. He examined the AI capability that a company builds and owns, set alongside its human capital. His point was that firms which only rent models risk having their expertise commoditized and firms that own a learning loop compound an advantage.

What Open-Source AI Means for THNQ Investors This is the rare structural shift where a thematic index captures both ends of the trade. The ROBO Global Artificial Intelligence Index (THNQ) holds the open-model makers giving their weights away — Meta, Alibaba, and Microsoft. It also holds the toll roads that those models run on — Nebius, Cloudflare, MediaTek, Astera Labs, and Credo. As intelligence commoditizes, the companies that we track on the infrastructure side collect the recurring economics that the model layer is shedding. For a primer on how that infrastructure layer fits together, see our Artificial Intelligence Content Hub.

Open-source is relocating the value in AI, moving it from the model to the systems that serve and deploy intelligence in the real world. Watch inference share of compute, ASIC server penetration, and enterprise agent adoption. Those three lines tell you where the token economy is heading, and THNQ is built to own the road it runs on.

Looking for regular updates? Subscribe here for weekly insights on robotics, AI, and healthcare technology, delivered straight to your inbox.

For more news, information, and analysis, visit the Artificial Intelligence Content Hub.

THNQ is the underlying index for the ROBO Global Artificial Intelligence ETF (THNQ) and the L&G Artificial Intelligence UCITS ETF (AIAI.LN).

*VettaFi is the index provider for the funds referenced and receives an index licensing fee. The funds are not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with their operation, marketing, or trading. This material is educational and analytical and is not individualized investment advice or a recommendation to buy or sell any security. Performance and data figures carry the as

Calgary, Alberta--(Newsfile Corp. - June 17, 2026) - Arrow Exploration Corp. (AIM: AXL) (TSXV: AXL) ("Arrow" or the "Company"), the high-growth operator with a portfolio of assets across key Colombian hydrocarbon basins, is pleased to provide an update on operational activity at the Icaco field on the Tapir Block in the Llanos Basin of Colombia where Arrow holds a 50 percent beneficial interest.

Icaco-2 Well

The Icaco 2 exploration well (IC-2) was spud May 18, 2026, and reached target depth on May 26, 2026. The IC-2 well was drilled, on time and under budget, to a total measured depth of 12,020 MD feet (Measured Depth), or 7,399 TVD feet (True Vertical Depth) and encountered multiple hydrocarbon-bearing intervals.

Log analysis shows 19.5 feet of net pay in the Carbonera C7 formation, 6 feet of net pay in the Gacheta formation and 74.5 feet of net pay in the Ubaque formation, for a total net pay of 100 feet TVD (True Vertical Depth).

The well is currently producing from the Ubaque formation, at a restricted rate, 35/128 choke and 37 Hz pump frequency, of approximately 830 BOPD gross (415 BOPD net). The oil quality is 13.4° API and there is a 1% water cut.

The ultimate flow rate will be determined in the first few weeks of production.

Initial production results are not necessarily indicative of long-term performance or ultimate recovery.

Forward Drilling Plans
The IC-4HZ well targeting the Ubaque was spud on June 13. Afterwards, the rig will move to drill the IC-3 vertical well targeting which has C7, Gacheta and Ubaque potential. The Company is constructing five additional cellars at the Icaco pad for a total of 7 additional cellars after IC-4HZ.

Production
Including the restricted production from the IC-2 well, total gross corporate production is approximately 5,000 boe/d. Currently the CN-HZ12 well is offline waiting on a workover. The well was producing approximately 330 BOPD gross (165 BOPD net) when it was shut in. Arrow has continued to shut in the Pepper gas field due to low natural gas prices in Alberta, which was producing approximately 130 boe/d when it was shut in. The Company believes that AECO gas prices will improve in the third and fourth quarter of 2026 once the region moves into the winter months. At that time the Pepper field is expected to be brought back on production.

Prices
During May 2026, Arrow oil field realized prices averaged approximately $97.48 US/barrel, which reflects the increase in Brent oil prices experienced by the unrest in the Middle East. Field prices reflect the deduction of the Vasconia differential and logistics fees (mostly transportation and quality differential).

Cash Balance
As of June 2, 2026, the Company's estimated cash balance is US$26.7 million. The Company continues to have no debt.

Tapir Extension

Arrow and its partner in the Tapir block have recently had encouraging meetings with Colombian authorities on the extension of the Tapir block. To date the dialog has been very constructive. Arrow believes that all conditions required for the extension to be granted have been met and management remains very confident that the extension will be granted. The Company will continue to update the market on developments as they occur. Colombian elections are also taking place this month and it is expected the next President of Colombia will be chosen on June 21, 2026.

Marshall Abbott, CEO of Arrow commented:

"The success of the Icaco-2 well indicates that the Icaco discovery may be material to Arrow. Future projects at Icaco are expected to include both horizontal and vertical development wells. The drilling results at Icaco so far have demonstrated 4 potential hydrocarbon bearing zones. This underlies the significant hydrocarbon density that exists in the Llanos basin and more exclusively in the Tapir Block.

"Arrow has spud its first horizontal well in the Ubaque Formation at the Icaco pad. Integrating multidimensional technical data supports significant flow potential in Icaco Ubaque wells. Strong netbacks and successful horizontal wells support payout occurring in months. This adds significant value and materially improves our positive balance sheet. We look forward to updating our shareholders on the progress at Icaco over the coming months."

For further Information, contact:

Arrow Exploration
Marshall Abbott, CEO+1 403 651 5995Joe McFarlane, CFO+1 403 818 1033

Canaccord Genuity (Nominated Advisor and Joint Broker)
Henry Fitzgerald-O'Connor+44 (0)20 7523 8000James Asensio Rory Blundell George Grainger    Auctus Advisors (Joint Broker)
Jonathan Wright +44 (0)7711 627449Rupert Holdsworth Hunt

Hannam & Partners (Joint Broker)
Leif Powis+44 20 7907 8500Samuel Merlin
  Camarco (Financial PR)
Owen Roberts +44 (0)20 3781 8331Rebecca Waterworth
About Arrow Exploration Corp.

Arrow Exploration Corp. (operating in Colombia via a branch of its 100% owned subsidiary Carrao Energy S.A.) is a publicly traded company with a portfolio of premier Colombian oil assets that are underexploited, under-explored and offer high potential growth. The Company's business plan is to expand oil production from some of Colombia's most active basins, including the Llanos, Middle Magdalena Valley (MMV) and Putumayo Basin. The asset base is predominantly operated with high working interests, and the Brent-linked light oil pricing exposure combines with low royalties to yield attractive potential operating margins. By way of a private commercial contract with the recognized interest holder before Ecopetrol S.A., Arrow is entitled to receive 50% of the production from the Tapir block. The formal assignment to the Company is subject to Ecopetrol's consent. Arrow's seasoned team is led by a hands-on executive team supported by an experienced board. Arrow is listed on the AIM market of the London Stock Exchange and on TSX Venture Exchange under the symbol "AXL".

Forward-looking Statements

This news release contains certain statements or disclosures relating to Arrow that are based on the expectations of its management as well as assumptions made by and information currently available to Arrow which may constitute forward-looking statements or information ("forward-looking statements") under applicable securities laws. All such statements and disclosures, other than those of historical fact, which address activities, events, outcomes, results or developments that Arrow anticipates or expects may, could or will occur in the future (in whole or in part) should be considered forward-looking statements. In some cases, forward-looking statements can be identified by the use of the words "continue", "expect", "opportunity", "plan", "potential" and "will" and similar expressions. The forward-looking statements contained in this news release reflect several material factors and expectations and assumptions of Arrow, including without limitation, Arrow's evaluation of the impacts of COVID-19, the potential of Arrow's Colombian and/or Canadian assets (or any of them individually), the prices of oil and/or natural gas, and Arrow's business plan to expand oil and gas production and achieve attractive potential operating margins. Arrow believes the expectations and assumptions reflected in the forward-looking statements are reasonable at this time, but no assurance can be given that these factors, expectations, and assumptions will prove to be correct.

The forward-looking statements included in this news release are not guarantees of future performance and should not be unduly relied upon. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company undertakes no obligations to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Qualified Person's Statement

The technical information contained in this announcement has been reviewed and approved by Grant Carnie, senior non-executive director of Arrow Exploration Corp. Mr. Carnie was formerly a member of the Canadian Society of Petroleum Geologists, holds a B.Sc. in Geology from the University of Alberta and has over 35 years' experience in the oil and gas industry.

This Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR").

Glossary Pay A reservoir or portion of a reservoir that contains economically producible hydrocarbonsNOT FOR RELEASE, DISTRIBUTION, PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301792

Source: Arrow Exploration Corp.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia

New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia

, /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced new data from studies of VOXZOGO® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the Endocrine Society Annual Meeting, in Chicago.

New data from a Phase 2, investigator-sponsored three-year extension study of VOXZOGO in 13 children with hypochondroplasia, led by Andrew Dauber, M.D. and investigators at Children's National Hospital, demonstrated sustained improvements in annualized growth velocity (AGV) and height standard deviation score (SDS), with a favorable safety profile. Mean height SDS improved by 0.72 SD over three years of treatment, while mean AGV increased from 4.27 cm/year at baseline to 7.24 cm/year at year one (p<0.001) and remained above baseline through years two and three.

BioMarin recently announced positive topline results from CANOPY-HCH-3, its registration-enabling Phase 3 pivotal study evaluating VOXZOGO in children with hypochondroplasia. These results will be included in the supplemental New Drug Application submission to the U.S. Food and Drug Administration planned for the third quarter of 2026.

"Building on the excellent Phase 3 results we recently announced, these new longer-term data further reinforce the potential of VOXZOGO to meaningfully improve growth outcomes for children with hypochondroplasia," said Greg Friberg, M.D., Executive Vice President and Chief Research & Development Officer at BioMarin. "Importantly, we continue to observe sustained growth improvements over time and a favorable safety profile, adding to the growing body of evidence supporting VOXZOGO for this potential new indication."

New BMN 333 Phase 1 Data Support Advancement Into Late-Stage Development

Additional data being presented at ENDO 2026 highlight the potential of investigational BMN 333, BioMarin's long-acting C-type natriuretic peptide (CNP) for achondroplasia. In a Phase 1 single-ascending dose study in healthy adults, BMN 333 demonstrated sustained systemic exposure associated with prolonged pharmacodynamic target engagement, supporting a weekly dosing schedule. The maximum examined dose of BMN 333 (500 μg/kg) increased exposure to free CNP by more than 13 times compared to another long-acting CNP agent, reflecting the potential of BMN 333 to become the new standard of care in achondroplasia. BMN 333 was well tolerated across all dose levels evaluated, with no dose-limiting toxicities or treatment-related serious adverse events. 

In April, BioMarin began enrolling patients in the registration-enabling Phase 2/3 study of BMN 333. A data update from the dose-finding segment of this study is expected in 2027.

Below are key presentations for achondroplasia and hypochondroplasia at ENDO, with all times listed in Central Daylight Time:

Vosoritide Treatment in Children With Hypochondroplasia: Three-Year Results From a Phase 2 Extension Trial
Oral Presentation #ORF47-08
Monday, June 15, 3 – 3:15 p.m.

BMN 333 Achieves High Sustained Released Vosoritide Exposure With Favorable Safety: Phase 1 Results That Support Phase 2/3 Trials in Achondroplasia
Poster Presentation #SUN-212 
Sunday, June 14, 9 a.m. – 4 p.m. 

About Achondroplasia

Achondroplasia, the most common form of skeletal dysplasia leading to disproportionate short stature in humans, is characterized by slowing of endochondral ossification, which results in disproportionate short stature and disordered architecture in the long bones, spine, face and base of the skull. This condition is caused by a change in the FGFR3 gene, a negative regulator of bone growth.

More than 80% of children with achondroplasia have parents of average stature and have the condition as the result of a spontaneous gene mutation. The worldwide incidence rate of achondroplasia is about one in 25,000 live births. VOXZOGO is being tested in children whose growth plates are still "open," typically those under 18 years of age. Approximately 25% of people with achondroplasia fall into this category.

About Hypochondroplasia

Hypochondroplasia is a rare, genetic skeletal dysplasia characterized by impaired bone growth, leading to disproportionate short stature and skeletal differences that can affect the long bones, spine and other parts of the skeleton and may impact physical functioning and overall quality of life. The condition presents with a broad and variable clinical spectrum and may include otolaryngologic (related to the ears, nose and throat) and neurological complications and is often diagnosed in toddlerhood or early school age based on clinical and radiological findings. BioMarin estimates that roughly 14,000 children with hypochondroplasia within the company's global footprint may be eligible for treatment with VOXZOGO.

There are currently no medicines approved by the U.S. Food and Drug Administration or the European Medicines Agency for the treatment of hypochondroplasia.

For more information about our clinical trials in hypochondroplasia, achondroplasia and other skeletal conditions, please visit clinicaltrials.biomarin.com.

About VOXZOGO

In children with achondroplasia, endochondral bone growth, an essential process by which bone tissue is created, is negatively regulated due to a gain of function mutation in FGFR3. VOXZOGO, a C-type natriuretic peptide (CNP) analog, acts as a positive regulator of the signaling pathway downstream of FGFR3 to promote endochondral bone growth.

VOXZOGO is the only approved medicine to support the growth of children with achondroplasia starting from birth, with international consensus guidelines recommending initiation of VOXZOGO as early as possible. First approved in 2021, VOXZOGO has helped more than 5,000 infants and children in more than 50 countries. Through our ongoing studies, BioMarin continues to evaluate VOXZOGO on key clinical endpoints relevant for achondroplasia patients, such as arm span, tibial bowing (leg bowing), body proportionality, spinal morphology (including spinal stenosis) and quality of life measures.

VOXZOGO is approved in the U.S., Japan and Australia to increase linear growth in children of all ages with achondroplasia with open epiphyses, and VOXZOGO is indicated in the EU for the treatment of achondroplasia in children 4 months of age and older whose epiphyses are not closed, as confirmed by appropriate genetic testing. In the U.S., this indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trial(s). To fulfill this post-marketing requirement, BioMarin intends to use the ongoing open-label extension studies compared to available natural history.

The use of VOXZOGO to treat hypochondroplasia has not yet been approved by any regulatory agency.

Patient Support Accessing VOXZOGO

BioMarin's robust support services have ensured a seamless treatment experience, spearheaded by Clinical Coordinators, who have conducted hundreds of trainings for families with achondroplasia since approval. BioMarin provides resources to support families navigating achondroplasia, including a caregiver mentorship program that connects parents with other caregivers, and a U.S. doctor directory that helps families and healthcare professionals identify clinicians experienced in achondroplasia care.

To reach a BioMarin RareConnections® Case Manager, please call, toll-free, 1-833-VOXZOGO (1-833-869-9646) or e-mail [email protected]. For more information about VOXZOGO, please visit www.voxzogo.com. For additional information regarding this product, please contact BioMarin Medical Information at [email protected].

VOXZOGO U.S. Important Safety Information

What is VOXZOGO used for?

VOXZOGO is a prescription medicine used to increase linear growth in children with achondroplasia and open growth plates (epiphyses). VOXZOGO is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. What is the most important safety information about VOXZOGO?

VOXZOGO may cause serious side effects including a temporary decrease in blood pressure in some patients. To reduce the risk of a decrease in blood pressure and associated symptoms (dizziness, feeling tired, or nausea), patients should eat a meal and drink 8 to 10 ounces of fluid within 1 hour before receiving VOXZOGO. What are the most common side effects of VOXZOGO?

The most common side effects of VOXZOGO include injection site reactions (including redness, itching, swelling, bruising, rash, hives, and injection site pain), high levels of blood alkaline phosphatase shown in blood tests, vomiting, joint pain, decreased blood pressure, and stomachache. These are not all the possible side effects of VOXZOGO. Ask your healthcare provider for medical advice about side effects, and about any side effects that bother the patient or that do not go away. How is VOXZOGO taken?

VOXZOGO is taken daily as an injection given under the skin, administered by a caregiver after a healthcare provider determines the caregiver is able to administer VOXZOGO. Do not try to inject VOXZOGO until you have been shown the right way by your healthcare provider. VOXZOGO is supplied with Instructions for Use that describe the steps for preparing, injecting, and disposing VOXZOGO. Caregivers should review the Instructions for Use for guidance and any time they receive a refill of VOXZOGO in case any changes have been made. Inject VOXZOGO 1 time every day, at about the same time each day. If a dose of VOXZOGO is missed, it can be given within 12 hours from the missed dose. After 12 hours, skip the missed dose and administer the next daily dose as usual. The dose of VOXZOGO is based on body weight. Your healthcare provider will adjust the dose based on changes in weight following regular check-ups. Your healthcare provider will monitor the patient's growth and tell you when to stop taking VOXZOGO if they determine the patient is no longer able to grow. Stop administering VOXZOGO if instructed by your healthcare provider. What should you tell the doctor before or during taking VOXZOGO?

Tell your doctor about all of the patient's medical conditions including If the patient has heart disease (cardiac or vascular disease), or if the patient is on blood pressure medicine (anti-hypertensive medicine). If the patient has kidney problems or renal impairment. If the patient is pregnant or plans to become pregnant. It is not known if VOXZOGO will harm the unborn baby. If the patient is breastfeeding or plans to breastfeed. It is not known if VOXZOGO passes into breast milk. Tell your doctor about all of the medicines the patient takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements. You may report side effects to BioMarin at 1-866-906-6100. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional safety information in the full Prescribing Information and Patient Information.

About BioMarin

BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.

Forward-Looking Statements

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including without limitation, statements about: the data to be presented at ENDO 2026, the Endocrine Society Annual Meeting, including oral and poster presentations; BioMarin's plans and expectations for the development of VOXZOGO for children with hypochondroplasia, including safety profile and potential benefits and plans to submit a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) during the third quarter of 2026; BioMarin's plans and expectations for the development of BMN 333 for children with achondroplasia, including plans to provide a data update from the dose finding segment of the registration-enabling Phase 2/3 study of BMN 333 in 2027; the safety profile and potential benefits of BMN 333, including the potential to become the new standard of care in achondroplasia; and BioMarin's estimate regarding total addressable patient population (TAPP) with respect to the conditions targeted by BioMarin's product candidates and commercial products, including hypochondroplasia. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others, any potential adverse events observed in the continuing monitoring of the patients in the clinical trials; the content and timing of decisions by the FDA, the European Medicines Agency, the European Commission and other regulatory authorities; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission (SEC), including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as such factors may be updated by any subsequent filings with the SEC. Investors are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, BioMarin RareConnections® and VOXZOGO® are registered trademarks of BioMarin Pharmaceutical Inc.

Contacts:

Investors                                                     

Media

Traci McCarty                                               

Andrew Villani

BioMarin Pharmaceutical Inc.                       

BioMarin Pharmaceutical Inc.

(415) 455-7558                                           

(628) 269-7393

SOURCE BioMarin Pharmaceutical Inc.

Cursor CEO and cofounder Michael Truell

Getty Images for HumanX Conference

On the heels of its blockbuster IPO, SpaceX announced that it plans to acquire AI coding startup Cursor in an all-stock deal worth $60 billion by the third quarter of 2026. The deal would double the net worths of Cursor’s four young billionaire cofounders, Michael Truell, 25, Aman Sanger, 25, Sualeh Asif, 25, and Arvid Lunnemark, 26. Forbes estimates they will be worth $2.7 billion each.

They aren’t the only ones poised for a windfall from the deal. Early investors including Andreessen Horowitz (which reportedly owns a roughly 10% stake, worth $6 billion) and Thrive (which owns about 7%, worth $4.2 billion, per a source familiar) stand to win big from the deal too.

Cursor has come a long way in a short span of time. Founded in 2022 by four MIT friends and 30 Under 30 alumni, the startup started out as a coding tool for developers. After AI behemoth Anthropic launched Claude Code, Cursor found itself on the defensive, shifting to “war time” mode, as Forbes reported in March.

It appears to have worked. In early June, Cursor crossed $4 billion in annualized revenue, fending off stiff competition from both Anthropic and OpenAI, Forbes reported. Its revenue grew from $2 billion in February to $3 billion in late April. The uptick in revenue is in part due its new product Cloud Agents, which works on complex programming tasks for hours in the background.

Cursor first teamed up with SpaceX in April, when the rocket maker obtained the right to acquire it for $60 billion, or pay $1.5 billion in breakup fees and $8.5 billion in computing resources if the deal didn’t go through. SpaceX, which also acquired xAI in February, had been struggling to improve the capabilities of its models as AI researchers left en masse. But it has a ton of compute, thanks to its gigantic Colossus supercomputer. For the past few months, the two companies have been jointly training a new AI model that will be released in Cursor and xAI’s Grok, SpaceX said in a post.

Now let’s get into the headlines.

BIG PLAYS

On Friday, Anthropic abruptly disabled its new AI model, Fable 5, after the U.S. government issued an order to ban foreign nationals from accessing it, citing national security concerns. The directive came after government officials learned of a way to jailbreak the powerful model’s safeguards. Fable 5, a more secure version of Anthropic’s Mythos family of models, had been in restricted access for months and was launched just days earlier to millions of people. A group of tech leaders including Amazon CEO Andy Jassy had flagged concerns over the model’s security risks to senior Trump officials last week, Reuters reported.

“You have to make a judgment call on these things,” Anthropic’s Chief Commercial Officer Paul Smith told Forbes just hours before the order was issued. “The safest you can be is to not let people use something. And then it’s totally safe. But then how is that helping the mission?”

Also notable: OpenAI’s spending reached $34 billion last year amid a neck-in-neck race with rival Anthropic to dominate the AI market, the Financial Times reported. The giant’s costs far outweigh the $13 billion in revenue it booked in 2025.

SHOW ME THE MONEY

SpaceX’s historic IPO made scores of stakeholders ultra-wealthy. The rocket maker and AI company started trading just before noon on Friday at $150 per share, implying an eye-popping $2 trillion valuation. CEO Elon Musk became the world’s first trillionaire. Early investors like Peter Thiel’s Founders Fund and Antonio Gracias’ Valor Equity Partners’ stakes in the company are worth $67 billion and $71 billion, respectively. As of Tuesday afternoon, SpaceX’s market cap had skyrocketed to $2.8 trillion, surpassing Amazon as the world’s fifth largest company by market value.

AI DEAL OF THE WEEK

Jeff Bezos’ AI venture Project Prometheus raised $12 billion in funding at a $41 billion valuation. Bezos runs the company as co-CEO with Vik Bajaj, a cofounder of Alphabet’s life sciences research lab Verily and a Stanford University professor. The nascent startup is building AI tools to help engineers design and manufacture physical products faster. It plans to use the funding to buy up compute, according to CNBC.

DEEP DIVE

If you’re interested in renting an apartment in one of Equity Residential’s 300 properties, chances are you’ll soon be chatting with Ella to set up an apartment tour or answer questions about a lease.

But Ella isn’t human. It’s an AI assistant that answers the phones and responds to hundreds of emails around the clock. It’s still sending quick replies after all the humans have gone home, when most inquiries typically come in.

Ella is so helpful that some people don’t realize they’re talking to a bot.

“Customers were calling in asking for Ella and saying, ‘We just love her work ethic.’ They wanted to make sure she was going to get her commission,” says Kristin Hupfer, a senior vice president of customer experience at Equity Residential. The firm discloses that Ella is an AI chatbot the first time it communicates with a person through email, phone or text, Hupfer says.

Ella has been a gamechanger for the Chicago-based property manager, which owns buildings in New York, San Francisco and Seattle. Back in 2018, the firm’s staff struggled to keep up with the influx of hundreds of requests from prospective tenants each week. That in turn meant losing customers to rivals and keeping units idle. Then in 2019, it started working with New York-based EliseAI, the developer of Ella. Now the bot handles 1.5 million texts, emails and phone calls every year, allowing Equity Residential to save $20 million in payroll costs, Hupfer says (no layoffs, she clarifies, just not replacing staff who left). The real estate firm owns two buildings in Jersey City that don’t need a human staff member at all because they can be managed from a nearby community and Ella handles all the administrative tasks.

Today one in six apartments in the U.S. and 90 percent of the country’s largest property managers use EliseAI’s tools to respond to questions about a unit, renew leases and triage maintenance requests. It can even use smart locks to let renters into an apartment for a tour, or determine that a request to fix a broken A/C unit in the summer should be prioritized.

Read the full story on Forbes.

MODEL BEHAVIOR

Anthropic’s AI models are incredibly powerful. That is, unless you’re an AI researcher developing frontier large language models that could eventually compete against them. Anthropic disclosed last week that its Fable 5 and Mythos 5 models deliberately become less helpful if they detect another AI research lab using them. Rather than outright refusing to produce an answer, the models secretly modify user prompts to change its own responses.

US Senator Elizabeth Warren, a Massachusetts Democrat, says President Donald Trump "can't point to where we're better off" after the war in Iran. Speaking on "Balance of Power: Evening Edition," Senator Warren also discusses Defense Secretary Pete Hegseth's military budget request, her criticisms of Kevin Warsh as chair of the Federal Reserve, the state of housing and the SpaceX IPO.

watch now

CNBC's Jim Cramer said Tuesday that investors flocking to SpaceX are betting on Elon Musk's ability to create transformative businesses — not the company's current earnings power.

"The stock is called SpaceX, but it might as well be called Elon Musk," the "Mad Money" host said.

SpaceX has quickly become one of the world's most valuable companies following its blockbuster IPO on Friday. Shares surged almost 5% Tuesday, pushing the rocket company's valuation above several technology heavyweights, including Amazon, and briefly surpassing Microsoft. The rally has intensified questions about whether SpaceX's roughly $2.5 trillion market value is justified.

Cramer argued, however, that conventional valuation methods miss what many investors are buying.

"There is no way this company, which could see losses for many years, deserves such a high valuation on its own. It only gets there because it's run by Musk," he said.

While Musk recently projected that SpaceX could generate $1 trillion in annual revenue by 2030, Cramer argued that the stock's appeal extends far beyond any single forecast. Instead, he thinks investors are assigning value to Musk's track record of building category-defining businesses and his ability to turn ambitious ideas into commercial opportunities.

"When you buy SpaceX here, you're really buying Elon Musk's brain," Cramer said. "I think the cult of Musk is for real."

To support that view, Cramer pointed to the breadth of SpaceX's businesses and growth initiatives, including its Starlink satellite internet network, reusable rocket operations, and long-term data center ambitions. Adding to that opportunity set, SpaceX announced Tuesday that it will acquire AI coding startup Cursor for $60 billion in stock, deepening its push into artificial intelligence and software development tools. While the company currently operates at a loss and many of these opportunities have yet to fully materialize, Cramer said they could ultimately become significant drivers of future growth.

Cramer suggested that some investors view SpaceX similarly to how previous generations viewed Berkshire Hathaway under Warren Buffett — a way to gain exposure to a business leader they believe can continue creating value for decades.

While skeptics continue to question the stock's valuation, Cramer noted that betting against the rally has been costly so far.

"While you're sitting here trying to justify SpaceX's valuation, the buyers are relentlessly pushing it up, and I bet they keep going," he said.

watch now

'Mad Money' host Jim Cramer discusses if SpaceX deserves its multi-trillion dollar valuation.

Buying AI coding agent Cursor in a $60 billion deal and renting out data-center capacity gives the company a launchpad to land more enterprise customers.

June 16, 2026 21:40 ET  | Source: Defiance ETFs

邁阿密, June 17, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs 今日宣佈推出 Defiance Daily Target 2X Short SpaceX ETF (SPCQ)，擴充其單一股票槓桿交易所買賣基金 (ETF) 系列。該系列專為希望放大投資創新增長公司曝險的活躍交易者而設。SPCQ 專為希望對 Space Exploration Technologies Corporation（「SpaceX」）(NASDAQ: SPCX) 獲得放大且短期反向曝險的交易者而設。SpaceX 乃領先的航空航天及衛星通訊公司，最近完成了首次公開招股，業務重點包括可重用發射系統、商業太空運輸，以及透過其星鏈 (Starlink) 網絡提供全球寬頻連接。

基金力求達致 SpaceX 股價每日百分比變動的 -200%，讓投資者得以在交易所買賣基金既便捷又透明的框架內，表達對該公司的策略性看淡觀點。

投資目標

基金的目標是在未計費用及開支前，達致 Space Exploration Technologies Corporation (NASDAQ: SPCX) 股價每日百分比變動負 2 倍 (-200%) 的每日反向投資結果。基金只尋求在單一交易日內實現所述投資目標，並不追求更長期的表現。

相關公司：Space Exploration Technologies Corporation（「SpaceX」）

Space Exploration Technologies Corporation 於 Nasdaq 股票市場上市，股票代號 SPCX，近期剛完成首次公開招股。該公司專注於設計、製造和發射先進的火箭及太空船。SpaceX 由 Elon Musk 於 2002 年創立，為商業、政府及國防客戶開發和營運運載火箭，同時透過其星鏈網絡提供衛星寬頻服務。公司是商業太空領域的領導先鋒，推動全球衛星通訊與軌道發射能力的發展。

投資交易所買賣基金並非直接投資於 SpaceX。

此基金並非適合所有投資者。此基金僅供具備知識的投資者所用。該等投資者須明白追求每日槓桿反向（負 2 倍）投資結果的潛在後果，通曉運用槓桿的風險，並願意時常監察其組合。此基金不擬供無意主動監察和管理投資組合的投資者使用，亦不適合該等投資者。此基金追求每日槓桿投資目標，亦即比不用槓桿的替代方案風險更高。此基金會放大相關證券的反向表現，而且只適合短期操作。若持有期超過一日，此基金的表現會是每日回報複合計算的結果，很可能與同期 SpaceX 回報的 -200% 出現差異。投資者有機會在一個交易日內損失全部本金。

媒體聯絡人：

Sylvia Jablonski
[email protected]
833.333.9383

重要披露事項

Defiance ETFs LLC 是此交易所買賣基金的發起機構。此基金的投資顧問為 Tidal Investments, LLC（「Tidal」或「顧問」）。

投資前，請仔細考慮此基金的投資目標、風險、收費及開支。招股章程及概要招股章程載有本投資公司的此等及其他重要資料。請於投資前細閱招股章程及/或概要招股章程。歡迎致電 833.333.9383 索取印刷版本。

投資涉及風險。可能損失本金。作為交易所買賣基金，此基金的交易價格可能高於或低於其資產淨值 (NAV)。股份以市價（而非資產淨值）買賣，且不允許從此基金單獨贖回。集中於單一發行方或行業的投資組合，可能會承受較高風險。此基金的策略不保證能適當實施，投資者可能損失部分或全部投資金額。

SPCX 價格上升風險。作為該基金反向投資策略的一部分，該基金會訂立基於 Space Exploration Technologies Corporation (NASDAQ: SPCX)（「相關證券」）股價的互換協議及期權合約。此策略會令該基金承受與沽空相關證券股份相似的若干風險，儘管基金實際上並無沽空亦然。此基金間接持有相關證券股價變動的負 2 倍曝險，故須面對相關證券股價上升的風險。一旦相關證券的股價上升，此基金很可能會貶值，並因此可能蒙受重大損失。此基金亦可能面臨以下風險：

間接投資 SpaceX 的風險。SpaceX 與信託、基金、顧問或其各自的關聯公司並無關連，亦毫無參與是次發行。SpaceX 在採取任何可能影響基金股份價值的企業行動時，並無義務考慮基金或其股東。投資此基金的投資者不會獲得與持有 SpaceX 股份相關的投票權或其他擁有權權益。

SpaceX 表現風險。SpaceX 可能無法實現其公開公佈的業務、發射運作、衛星部署或商業增長計劃的預期，這或會引致相關證券的價值下跌。SpaceX 所處的行業資本密集且技術極為複雜，發射失敗、製造缺陷、部署進度延誤或營運中斷，均可能對其業務及財務狀況造成重大影響。

商業太空行業風險。從事商業太空行業的公司，其營運環境有以下特點：快速創新、開發成本高昂、監管規例多變以及需求不確定。這些企業能否成功，取決於能否保持技術競爭力、實施可靠發射，以及確保持續的資金來源及客戶需求。競爭加劇、監管政策轉變、發射失敗或政府削減開支，均可能不利於 SpaceX 及基金的表現。

衛星通訊行業風險。從事衛星通訊及寬頻服務的公司，面臨重大的營運、技術及競爭風險。這類業務需要對衛星星座、基礎設施及網絡運作投入大量資金，並且依賴監管機構持續批准其使用頻譜及軌道位置。來自地面寬頻供應商及其他衛星營運商的競爭，可能限制增長機會，並對相關證券造成負面影響。

Elon Musk 影響風險。SpaceX 的價值可能因 Elon Musk 的行為、決策及公開言論而受顯著影響。公眾對 Musk（馬斯克）先生、其領導能力或其參與其他業務的觀感，可能會實質影響到投資者的情緒及相關證券的表現。

單一發行者風險。基於發行者特有的屬性，投資該基金可能比傳統的風險分散型或被動追蹤大市的匯集投資更為波動。面對影響 SpaceX 的事件時，此基金的價值波動幅度，可能會比那些投資於更廣泛發行者的基金更為劇烈。

近期首次公開招股及衍生工具容量限制風險。此基金能否達成每日槓桿投資目標，部分取決於能否獲得提供相關證券曝險的互換、期權及其他金融工具。對於一間剛上市不久的公司，這些工具可能相當有限、流動不足、成本昂貴，甚至無法取得，尤其是在首次公開招股後不久，或市場出現重大波動或需求熾熱之時。

複合效應與市場波動風險。此基金若持有超過一個交易日，其表現將源於期內每日回報的複合效應，此結果極可能與相關證券表現的 200% 不符。在波動較劇烈的時期，即使相關證券的股價在較長線而言有所上升，複合效應仍可能令此基金的價值受損。

每日關聯性 / 追蹤風險。無法保證此基金能高度配合相關證券的槓桿關聯性。市場干擾、波動或衍生工具供應受限，均可能導致此基金的表現偏離其每日槓桿投資目標。

槓桿風險。此基金將借助金融工具尋求 2 倍的長倉曝險，這令基金須面對損失可能放大的風險。槓桿運作會令此基金更加波動，相關證券股價即使只出現相對微小的變動，亦可能導致基金承受重大虧損。

交易對手風險。此基金運用衍生工具，因此須承擔交易對手風險。一旦交易對手未能履行其合約義務，基金可能出現延誤或招致損失，進而對其表現構成負面打擊。

衍生工具風險。基金投資衍生工具所帶來的風險，可能比直接投資證券更高。此等風險涵蓋波動性加劇、與相關證券的關聯性存在誤差、流動性掣肘、估值複雜難解，以及虧損可能超出最初投資金額。

重新平衡風險。倘若此基金未能正確或及時地重新平衡其投資組合，其曝險水平可能與其投資目標不符。這或會增加此基金所承擔的風險，並使其表現偏離原本預期的每日槓桿結果。

非分散投資風險。此基金並非採取分散投資策略，因而可能將較高比例的資產投資於單一發行者。因此，與分散投資的基金相比，對於影響 SpaceX 的不利事件，此基金的反應會更為敏感。

互換協議。運用互換交易乃高度專門活動，其所涉投資技巧及風險，有別於一般投資組合證券交易。

固定收益證券風險。當此基金投資於固定收益證券時，閣下在此基金的投資價值將隨著利率變化而波動。

高投資組合周轉率風險。每日重新平衡預期會帶來較高的投資組合周轉率。高周轉率可能增加交易成本，從而削弱基金回報，並可能導致股東須就較高分派金額繳稅。

流動性風險。此基金所持有的部分證券或金融工具可能難以沽售，在市場受壓或波動的時期尤甚。流動性下降可能令基金難以調整其曝險水平，或難以達致其投資目標。

新基金風險。此基金是新近成立的管理投資公司，營運紀錄有限。因此，可供投資者評估基金過往表現的數據有限。

基金由 Foreside Fund Services, LLC 發行。

請瀏覽以下網址，查閱此公告隨附的相片：https://www.globenewswire.com/NewsRoom/AttachmentNg/ab71dab4-a168-4a8c-98b0-f191b922e095 

SpaceX options on their first day of trading showed about a 15% chance for the stock to rise by 50% and a similar possibility that it loses half its value in the next three months, according to Susquehanna.

The stock saw the fifth-highest call volume of the day, Susquehanna strategist Chris Murphy wrote in a note Tuesday.

"The largest trades increasingly looked like hedges tied to future supply risk," Murphy wrote. "Upside calls reflect demand for another sharp move higher, while downside puts reflect concern around lock-up supply, valuation risk, and the possibility that the initial post-listing enthusiasm fades. The result is a difficult trading setup. The tails look too expensive to buy, but they also look too dangerous to sell."

SpaceX's stock rose for another day after its initial public offering on Friday — it's up about 50% from its IPO price — and its market cap has surpassed Amazon and is close to Microsoft's valuation. The options reflect a vigorous debate about whether the company can live up to the initial enthusiasm.

Current pricing implies about a 15% probability that SpaceX rises another 50% by September, while also implying roughly a 13% chance the stock falls 50%, Murphy wrote.

Investors are "trading the story, they're trading the action, they're trading the excitement, they're trading Elon Musk, but at some point the rubber meets the road in terms of the fundamentals having to match up with that excitement," Peter Boockvar, chief investment officer at One Point BFG Wealth Partners, said on CNBC's "Squawk Box Asia."

"If they can deliver, then the upside is certainly there, but the valuation is so enormous that the company is going to really have to show itself in growing into that valuation," he added. "I think that that's going to take at least a couple of years."

Elon Musk's Space Exploration Technologies Corp. (NASDAQ:SPCX) has completed its initial public offering (IPO) and now all eyes are on the company's next move.

Musk's Mars AmbitionsOne of Musk's goals has been to reach Mars, colonize it and build a city on it. This goal was also part of a performance target for the world's richest man, as revealed by SpaceX's IPO paperwork.

Here's What Prediction Market Is SayingWhile Musk has made reaching Mars one of his biggest goals, prediction markets are not very confident about the trillionaire being able to achieve it.

Data from Kalshi, a federally authorized betting platform, shows that over $101,000 has been bet on the contract "Will Elon Musk visit Mars in his lifetime?"

According to bettors, the probability of Musk reaching Mars in his lifetime is just 13%.

Disclaimer: Kalshi and Benzinga have an existing data collaboration agreement.

What Will Musk Get?If Musk is able to help SpaceX establish a permanent human settlement on Mars with at least one million residents, along with the company hitting a $7.5 trillion valuation, he stands to receive 200 million super-voting restricted shares.

The goal is still a long time away, with Musk himself admitting that it was a long way off.

In February, Musk revealed that SpaceX's Mars timeline was slipping by "five to seven years," so the company could focus on lunar missions first.

Prediction Market Bets On Starlink IPOJust days after SpaceX wrapped up its IPO, the prediction market is now betting on Starlink's IPO. Bettors have placed a very low probability on Starlink going public before June 2027.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo courtesy: Shutterstock.com

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

SpaceX’s new options market exploded on Tuesday, giving traders a fresh and far riskier way to bet on the rocket company’s post-IPO surge.

The contracts began trading only days after SpaceX’s blockbuster Nasdaq debut, and demand was immediate.

Call options, which profit when a stock rises, dominated early activity. But the pricing also showed something more complicated than simple excitement.

Wall Street is now bracing for a huge move in either direction, with traders seeing room for another sharp rally while also preparing for a painful reversal.

SpaceX priced its IPO at $135 a share last week, already making it one of the most closely watched listings in market history.

Since then, the stock has climbed roughly 50%, lifting the company’s market value past Amazon and briefly above Microsoft during Tuesday’s trading.

That speed matters, as normally, a stock needs time to settle after going public.

In SpaceX’s case, investors have rushed in almost immediately, helped by the company’s rare mix of space launches, Starlink, defence contracts, artificial intelligence ambitions, and Elon Musk’s personal following.

The rally has also created pent-up demand among investors who either received small IPO allocations or missed out entirely. For them, options offer another route in.

An option is a contract that gives the buyer the right, but not the obligation, to buy or sell a stock at a fixed price before a set date.

A call is a bet on upside. A put is protection, or a bet, against downside. With SpaceX moving so fast, both sides have become expensive.

The scale of Tuesday’s options debut was striking. Around 1.8 million SpaceX options contracts changed hands, far above Meta’s previous first-day options record in 2012.

Calls outpaced puts, showing that bullish demand remained strong even after the stock’s dramatic run.

Susquehanna said SpaceX had the fifth-highest call volume of any stock that day.

Data from Trade Alert indicates that SpaceX options were the third-most heavily traded single-stock contracts overall, behind only Tesla and Nvidia.

“It’s unusual in history for companies to have options trade so quickly,” Mike Khouw, chief strategist at YieldMax ETFs, told Yahoo Finance.

“This is the third busiest single stock options contract trading today.”

The bigger story was not just volume. It was what the options prices implied about future movement.

Susquehanna estimated that the market was pricing roughly a 15% chance that SpaceX rises another 50% over the next three months.

It was also pricing a similar chance that the stock loses half its value over the same period.

That is what traders mean when they talk about “tails.” It refers to extreme outcomes at either end of the range.

In this case, the market is saying SpaceX could keep ripping higher, or crack sharply, and neither outcome looks remote.

Also read- SpaceX stock soars after IPO: Will it follow the Circle, Figma, Klarna path?

That two-sided risk is why derivatives strategists are sounding cautious, even as volume booms.

“The tails look too expensive to buy, but they also look too dangerous to sell,” Chris Murphy, a strategist at Susquehanna, said in comments cited by CNBC.

The line captures the problem facing traders. Buying options is costly because implied volatility is high. Implied volatility is the market’s estimate of how violently a stock may move.

But selling options can be even riskier, because a sharp move either way could leave sellers exposed to steep losses.

On the upside, call buyers are betting SpaceX can repeat the kind of momentum seen in Tesla during its most speculative phases.

On the downside, put demand reflects concern about valuation, lock-up expiry risk, and the possibility that early excitement fades once more shares become available.

Reuters reported that one large September trade appeared to hedge against the stock falling below $205, likely linked to future share supply after IPO lock-up restrictions ease.

Sceptics say the valuation already leaves little room for error.

“Investors rarely make money buying stocks valued at over 100x revenue,” short seller Jim Chanos told Yahoo Finance, while still acknowledging that Starlink is “a real business.”

CHEVY CHASE, Md., June 16, 2026 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced a select number of move-in ready townhomes are now available in its Chevy Chase Crossing community, located just a 10-minute drive from Washington, D.C. The Sales Center is open daily at 3530 Manor Rd in Chevy Chase, Maryland.

Chevy Chase Crossing offers new luxury townhomes ranging from approximately 2,400 to over 3,600 square feet. Two collections of modern home designs feature rooftop terraces, two-car garages, open kitchens and great rooms, luxurious primary bedroom suites and spacious secondary bedrooms, convenient bedroom-level laundry rooms, flex rooms, and elevator options. Homes are priced from $1.12 million.

“Chevy Chase Crossing offers the rare opportunity to own a beautiful new Toll Brothers home that is move-in ready, with design options selected by a professional designer at the Toll Brothers Design Studio,” said Nimita Shah, Division President of Toll Brothers in D.C. Metro. “Our quick move-in homes are an incredible option for buyers who want to begin living in their new dream home as soon as possible.”

Located along the future Purple Line transit station, Chevy Chase Crossing offers unmatched accessibility to major commuting routes, including I-495 and Connecticut Avenue. Residents will enjoy proximity to Chevy Chase Lake retail, Bethesda Row, The Shops at Wisconsin Place, and Chevy Chase Pavilion, as well as abundant dining, entertainment, and recreational options. The community is also assigned to highly rated Montgomery County Public Schools.

For more information on Chevy Chase Crossing, call 866-232-1718 or visit ChevyChaseCrossing.com.

About Toll Brothers

Toll Brothers, Inc., a Fortune 500 Company, is the nation’s leading builder of luxury homes. The Company was founded in 1967 and became a public company in 1986 with common stock listed on the New York Stock Exchange under the symbol “TOL.” Toll Brothers builds new homes and communities in over 60 markets across the United States, serving first-time, move-up, active-adult, and second-home buyers. The Company also operates its own architectural, engineering, mortgage, title, land development, smart home technology, landscape, and building components manufacturing businesses.

Toll Brothers was named the #1 Most Admired Home Builder in Fortune magazine’s 2026 list of the World’s Most Admired Companies®, the ninth year the Company has achieved this honor. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit TollBrothers.com.

From Fortune, ©2026 Fortune Media IP Limited. All rights reserved. Used under license.

Contact: Andrea Meck | Toll Brothers, Senior Director, Public Relations & Social Media | 215-938-8169 | [email protected]

Photos accompanying this announcement are available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/730ac9dd-862a-4e98-a3a8-b7df8544c6c0

https://www.globenewswire.com/NewsRoom/AttachmentNg/1a121e3f-77cb-43a6-9436-8a04d77d31a8

https://www.globenewswire.com/NewsRoom/AttachmentNg/3969512b-a87d-413b-b9f9-61c79f6b3dc1 

Sent by Toll Brothers via Regional Globe Newswire (TOLL-REG)

By You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Anthropic is far from the first first Silicon Valley giant to trigger US government export controls. Apple turned the prospect of a 1999 export limit on the Power Mac G4 into an ad campaign. JOHN G. MABANGLO / AFP via Getty Images Sometimes, the US government's concerns that a powerful new tech product could fall into the wrong hands can be a marketing opportunity. Just look at Steve Jobs and Apple back in 1999.

In August of that year, Jobs, who was then Apple's interim-CEO, took the stage to unveil the company's new desktop "supercomputer": the Power Mac G4. Jobs called it "the most powerful personal computer ever brought to market," CBS News reported at the time.

The only issue was all that computing power technically meant that the device crossed the threshold that would trigger US export controls limiting which countries Apple could ship the computer to.

Jobs highlighted the distinction in the wake of the computer's unveiling.

"The Power Mac G4 is so fast that it is classified as a supercomputer by the US government, and we are prohibited from exporting it to over 50 nations worldwide," Jobs said the Apple Expo, CNN reported in September 1999.

The restriction Apple faced at the time stemmed from a Government Accountability Office report that called 50 countries a concern "for military or proliferation reasons," with seven others facing near-embargo restrictions on computer exports.

Jobs told the audience that the new Macs, capable of operating at up to one gigaflop, could not be exported to the nations in that report, including China, Iraq, and North Korea.

Now — as Anthropic faces US export restrictions for its Fable 5 and Mythos 5 AI models — Jobs' computer unveiling and subsequent marketing have renewed relevance.

Behind the scenes, Apple pushed to ease the US restrictions (and was eventually successful). In public, Apple leaned into the US government's concerns in an ad campaign recently resurfaced by Tom's Hardware.

Fable isn't the first.

In 1999 the department of defense blocked exports of the PowerMac G4 for crossing the 1 gigaflop threshold.

Steve Jobs turned it into an ad. pic.twitter.com/yHoyJjpSke

— Justin Schroeder (@jpschroeder) June 13, 2026 The commercial showed tanks surrounding the Power Mac G4 as a voiceover declares that, "For the first time in history, a personal computer has been classified as a weapon by the US government."

The commercial ended with a jab at Intel-powered PCs: "Well, they're harmless," the voiceover said.

Apple's 1999 run-in with export controls was an earlier example of Washington treating cutting-edge commercial technology as a national-security concern.

Today, there's an AI-flavored twist that's landed Anthropic into very real hot water. Over the weekend, the Trump administration ordered Anthropic to restrict foreign nationals' access to its Fable 5 and Mythos 5 models, citing national security concerns related to a possible jailbreak to get around safeguards.

Anthropic disabled the AI models for all customers while it works to clear up what it described as a misunderstanding from the White House. The company has disputed the severity of the issue that was originally flagged to the White House.

Anthropic has long championed its focus on AI safety, and earlier this year said its Mythos Preview model was too powerful to release widely due to its hacking abilities, instead offering early access to selected partners to help bolster cybersecurity safeguards.

The severity of the White House's Anthropic order means it's not exactly an apples-to-apples comparison (pun intended) to Steve Jobs and Apple in 1999. After all, Apple was still able to launch and sell its Power Mac G4s.

But if Anthropic manages to smooth over its latest clash with the US government and re-launch its Fable 5 and Mythos models, Jobs and Apple demonstrated decades ago that having a product so powerful it raises government export concerns doesn't have to be all bad.

Read next

Ben Shimkus You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Ben Shimkus is a reporter for the Business News desk. He writes about cars, transportation, retail, and jobs. Ben's reporting has appeared in Rolling Stone, The Verge, Automotive News, USA Today, AutoBody News, LGBTQ Nation, TopSpeed, and Out Magazine. He's also held staff writing positions at The U.S. Sun and the Daily Mail. He graduated from NYU with a Master's in journalism in 2024. Email Ben at [email protected] or message him privately on Signal at bshimkus.41. 

Apple Anthropic

Apple stock isn't moving higher since its WWDC. However, the iPhone maker's AI strategy could bear fruit, according to Citi analysts.

Apple's Indian supplier ‌Tata Electronics on Tuesday said a state pollution control board has dropped its scrutiny of the company's iPhone components plant after it addressed concerns about contamination.

WICHITA, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Legend Senior Living, a Wichita-based senior housing provider, has welcomed Apple Blossom Senior Living in Moon Township, Pennsylvania as the newest community in its growing portfolio, marking another significant step in the company's strategic growth across the Commonwealth.

With the addition of Apple Blossom Senior Living, Legend now operates 78 senior living residences across eight states and brings its personalized approach to senior living to even more families throughout Pennsylvania.

Located in Moon Township near Pittsburgh, Apple Blossom Senior Living offers a full continuum of lifestyle and care options, including Independent Living cottages, as well as Personal Care and Memory Care options. The community is known for its welcoming environment, personalized support, and commitment to helping older adults live with purpose, dignity, and independence.

"The addition of Apple Blossom represents an exciting milestone for Legend as we continue to expand our presence in Pennsylvania," said Matt Buchanan, President and Co-CEO of Legend Senior Living. "Pennsylvania has become an increasingly important market for us, and Apple Blossom is a wonderful addition to our growing family of communities. We are honored to serve the residents who call Apple Blossom home and look forward to building upon the strong reputation and relationships that already exist within the community."

This expansion further strengthens Legend's position as a leading provider of senior living services throughout Pennsylvania, where the company has continued to invest in communities that offer exceptional experiences for residents and families.

Residents of Apple Blossom Senior Living can expect a seamless transition and continued commitment to quality care, meaningful engagement, and personalized services. Legend's family-led approach emphasizes individualized support, strong relationships, and creating environments where older adults can thrive physically, socially, emotionally, and spiritually.

About Legend Senior Living
Legend Senior Living is a privately held senior housing and services company based in Wichita, Kansas. Legend owns and operates more than 75 residences — spanning Independent Living, Assisted Living, Memory Care and Personal Care — in Colorado, Florida, Kansas, Missouri, New Jersey, Oklahoma, Pennsylvania, and Texas. Founded more than 25 years ago, Legend Senior Living remains family-owned and family-led, with a long-standing reputation for operational excellence, innovative programming, and resident-centered care.
www.legendseniorliving.com

FOR MORE INFORMATION:
Rebecca Butler
Vice President of Marketing & Brand Strategy
Legend Senior Living
[email protected]
Phone: 316-616-6288

Apple Blossom Senior Living
www.appleblossomseniorliving.com
125 Apple Blossom Way
Moon Township, PA 15108
412-539-6446